Daiichi Sankyo Appoints Hiroyuki Okuzawa To Succeed Sunao Manabe As CEO
Japanese healthcare firm Daiichi Sankyo Co., Ltd (DSKYF.PK) announced Friday the appointment of Hiroyuki Okuzawa as Chief Executive ...
FDA Approves AstraZeneca And Daiichi Sankyo's ENHERTU For HER2-Low/Ultralow Breast Cancer
The U.S. Food and Drug Administration has approved AstraZeneca Plc. (AZN.L, AZN) and Daiichi Sankyo's (DSKYF.PK) ENHERTU ...
BioSpace4d
Daiichi Sankyo Admits 2024 Wasn’t ‘Perfect’ but 2025 Is Starting Off With a Bang
The Japanese pharma had one asset rejected by the FDA and withdrew a regulatory application for another, but already this ...
Philippine Daily Inquirer14d
Enrile questions INC ‘logic’ vs VP Sara Duterte impeach raps
In a Facebook post on Wednesday night, two days after the INC’s “National Rally for Peace,” the 100-year-old former Senate President challenged the INC’s supposed support of President ...
Wall Street Journal14d
Daiichi Sankyo Co. Ltd.
1 Day DSKYF 10.11% DJIA 1.65% S&P 500 1.83% Health Care/Life Sciences 0.69% ...
Business Wire18d
Daiichi Sankyo Acquires Intellectual Property Rights for Anti-TA-MUC1 Antibody in DS-3939 from Glycotope GmbH
are being jointly developed and commercialized globally with Merck & Co., Inc, Rahway, NJ, USA. DS-3939, a TA-MUC1 directed ADC, is being developed by Daiichi Sankyo. The second Daiichi Sankyo ADC ...
Morningstar21d
Daiichi Sankyo Co Ltd
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...